quote:

A common type of targeted therapy is directed against a molecule known as epidermal growth factor receptor (EGFR). Although EGFR fuels the growth of cancer cells, it also plays a role in the normal growth of the skin, hair, and nails. That means rashes and changes to the hair and nails may occur after treatment with these drugs, including cetuximab (Erbitux), erlotinib (Tarceva), panitumumab (Vectibix), and lapatinib (Tykerb).

quote:

Sorafenib (Nexavar) and sunitinib (Sutent) are two drugs that interact with multiple targets to stop or slow cancer growth. Most skin reactions are mild and manageable. However, 20% to 40% of people taking these drugs experience painful, thickened areas of skin on the hands and fee that may blister. These areas may also become tender to the point that they interfere with the person's daily activities, such as walking or holding objects.

In 20% to 40% of patients, a rash that may involve redness and a sensation of warmth or burning on the face or scalp occurs. Mild hair loss may be a side effect for up to 25% of patients on sorafenib, but it tends to be mild. Dry skin is also common and should be treated early to prevent the development of itching.